Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation

Clinical Therapeutics

Volumn 35, Issue 11, 2013, Pages 1762-1769

  Vannaprasaht, Suda ^a   Reungjui, Sirirat ^b   Supanya, Darika ^a   Sirivongs, Dhavee ^b   Pongskul, Cholatip ^b   Avihingsanon, Yingyos ^c   Tassaneeyakul, Wichittra ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

CYP3A5 genotype; dosage regimen; induction dose; kidney transplantation; maintenance dose; tacrolimus

Indexed keywords

AMLODIPINE; ATORVASTATIN; CYTOCHROME P450 3A5; FELODIPINE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; SIMVASTATIN; TACROLIMUS;

ADULT; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HUMAN; INDUCTION CHEMOTHERAPY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE CHEMOTHERAPY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

CYP3A5 GENOTYPE; DOSAGE REGIMEN; INDUCTION DOSE; KIDNEY TRANSPLANTATION; MAINTENANCE DOSE; TACROLIMUS;

ADULT; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONS; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 84888015274     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.08.019     Document Type: Article

References (34)

1. Y. Dai, M.F. Hebert, and N. Isoherranen Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro Drug Metab Dispos 34 2006 836 847
2. L.J. Scott, K. McKeage, S.J. Keam, and G.L. Plosker Tacrolimus: a further update of its use in the management of organ transplantation Drugs 63 2003 1247 1297
3. M. Mourad, P. Wallemacq, and M. De Meyer The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function Clin Chem Lab Med 44 2006 1192 1198
4. C.E. Staatz, and S.E. Tett Pharmacokinetic considerations relating to tacrolimus dosing in the elderly Drugs Aging 22 2005 541 557
5. A.K. Daly Significance of the minor cytochrome P450 3A isoforms Clin Pharmacokinet 45 2006 13 31
6. I. Koch, R. Weil, and R. Wolbold Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA Drug Metab Dispos 30 2002 1108 1114
7. P. Kuehl, J. Zhang, and Y. Lin Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383 391
8. L.K. Kamdem, F. Streit, and U.M. Zanger Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus Clin Chem 51 2005 1374 1381
9. C.E. Staatz, L.K. Goodman, and S.E. Tett Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II Clin Pharmacokinet 49 2010 207 221
10. C.E. Staatz, L.K. Goodman, and S.E. Tett Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I Clin Pharmacokinet 49 2010 141 175
11. V. Haufroid, P. Wallemacq, and V. VanKerckhove CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study Am J Transplant 6 2006 2706 2713
12. J. Schiff, E. Cole, and M. Cantarovich Therapeutic monitoring of calcineurin inhibitors for the nephrologist Clin J Am Soc Nephrol 2 2007 374 384
13. I.A. Macphee, S. Fredericks, and T. Tai Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement Transplantation 74 2002 1486 1489
14. E. Thervet, D. Anglicheau, and B. King Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients Transplantation 76 2003 1233 1235
15. V. Haufroid, M. Mourad, and V. Van Kerckhove The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 2004 147 154
16. N. Tsuchiya, S. Satoh, and H. Tada Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 2004 1182 1187
17. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano Human P-glycoprotein transports cyclosporin A and FK506 J Biol Chem 268 1993 6077 6080
18. U.L. Larsen, L. Hyldahl Olesen, and C. Guldborg Nyvold Human intestinal P-glycoprotein activity estimated by the model substrate digoxin Scand J Clin Lab Invest 67 2007 123 134
19. D. Anglicheau, C. Verstuyft, and P. Laurent-Puig Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients J Am Soc Nephrol 14 2003 1889 1896
20. D. Li, R. Gui, J. Li, Z. Huang, and X. Nie Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms Transplant Proc 38 2006 2850 2852
21. D.A. Hesselink, R.H. van Schaik, and I.P. van der Heiden Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 2003 245 254
22. E. Hustert, M. Haberl, and O. Burk The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 2001 773 779
23. J.K. Lamba, Y.S. Lin, E.G. Schuetz, and K.E. Thummel Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 2002 1271 1294
24. J.H. Choi, Y.J. Lee, S.B. Jang, J.E. Lee, K.H. Kim, and K. Park Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects Br J Clin Pharmacol 64 2007 185 191
25. I.A. MacPhee, S. Fredericks, and T. Tai The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 2004 914 919
26. X. Zhang, Z.H. Liu, and J.M. Zheng Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation Clin Transplant 19 2005 638 643
27. A. Provenzani, M. Notarbartolo, and M. Labbozzetta The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients Ann Transplant 14 2009 23 31
28. D.R. Kuypers, H. de Jonge, M. Naesens, and Y. Vanrenterghem A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients Clin Ther 32 2010 2012 2023
29. D.R. Kuypers, M. Naesens, H. de Jonge, E. Lerut, K. Verbeke, and Y. Vanrenterghem Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients Ther Drug Monit 32 2010 394 404
30. H.L. Tang, H.G. Xie, Y. Yao, and Y.F. Hu Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers Pharmacogenet Genomics 21 2011 713 720
31. F. Glowacki, A. Lionet, and D. Buob CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation Nephrol Dial Transplant 26 2011 3046 3050
32. S. Hoffmeyer, O. Burk, and O. von Richter Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478
33. Y. Li, X. Hu, and B. Cai Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients Transpl Immunol 27 2012 12 18
34. R.A. Op den Buijsch, M.H. Christiaans, and L.M. Stolk Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms Fundam Clin Pharmacol 21 2007 427 435